ISSN 2412-4036 (print)
ISSN 2713-1823 (online)

Phenotypes of hip osteoarthritis and the potential for personalized local injection therapy

O.V. Teplyakova

1) Ural State Medical University, Ekaterinburg, Russian Federation; 2) Medical Association “New Hospital”, Ekaterinburg, Russian Federation
Abstract. Hip osteoarthritis (OA) is a heterogeneous disease; however, there is currently no universally accepted classification of hip OA phenotypes. Various morphological variants of this disease are distinguished, resulting from joint developmental anomalies (acetabular dysplasia, femoroacetabular impingement). In terms of clinical course, rapidly progressive hip OA is distinguished; it leads to joint collapse within a few months. Taking the psychotype into account, a maladaptive OA phenotype (approximately 34% of cases) is identified, characterized by pronounced anxiety, depression, and kinesiophobia. Pathogenetically, hip OA is always based on a combination of biomechanical overload and local inflammation. Consequently, the use of intra-articular hyaluronic acid (HA) injections is well-founded. A promising approach to its treatment is the use of hybrid implants, such as Flexotron® Ultra M. The two-phase structure of the drug (hyaluronic acid with a molecular weight of 3200 and 1200 kDa) provides synergy: the restoration of synovial fluid rheology and the modulation of pro-inflammatory cascades.

Keywords

osteoarthritis
hip joint
phenotypes of hip osteoarthritis
femoroacetabular impingement
hyaluronic acid

References

  1. Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis Cartilage. 2015;23(8):1233–41.

    PMID: 25865392. PMCID: PMC4516635. https://doi.org/10.1016/j.joca.2015.03.036

  2. Mobasheri A, Kapoor M, Ali SA, Lang A, Madry H. The future of deep phenotyping in osteoarthritis: How can high throughput omics technologies advance our understanding of the cellular and molecular taxonomy of the disease? Osteoarthr Cartil Open. 2021;3(4):100144.

    PMID: 36474763. PMCID: PMC9718223. https://doi.org/10.1016/j.ocarto.2021.100144

  3. Im GI, Moon JY. Emerging concepts of endotypes/phenotypes in regenerative medicine for osteoarthritis. Tissue Eng Regen Med. 2022;19(2):321–24.

    PMID: 34674181. PMCID: PMC8971261. https://doi.org/10.1007/s13770-021-00397-2

  4. Deveza LA, Nelson AE, Loeser RF. Phenotypes of osteoarthritis: Current state and future implications. Clin Exp Rheumatol. 2019;37 Suppl 120(5):64–72. PMID: 31621574. PMCID: PMC6936212.
  5. Hall M, van der Esch M, Hinman RS, Peat G, de Zwart A, Quicke JG, et al. How does hip osteoarthritis differ from knee osteoarthritis? Osteoarthritis Cartilage. 2022;30(1):32–41.

    PMID: 34600121. https://doi.org/10.1016/j.joca.2021.09.010

  6. Tateuchi H, Akiyama H, Goto K, So K, Kuroda Y, Ichihashi N. Clinical phenotypes based on clinical prognostic factors in patients with secondary hip osteoarthritis: Preliminary findings from a prospective cohort study. Clin Rheumatol. 2020;39(7):2207–17.

    PMID: 32088798. https://doi.org/10.1007/s10067-020-04988-7

  7. Rossi-deVries J, Pedoia V, Samaan MA, Ferguson AR, Souza RB, Majumdar S. Using multidimensional topological data analysis to identify traits of hip osteoarthritis. J Magn Reson Imaging. 2018;48(4):1046–58.

    PMID: 29734501. PMCID: PMC6174097. https://doi.org/10.1002/jmri.26029

  8. Roemer FW, Jarraya M, Collins JE, Kwoh CK, Hayashi D, Hunter DJ, Guermazi A. Structural phenotypes of knee osteoarthritis: Potential clinical and research relevance. Skeletal Radiol. 2023;52(11):2021–30.

    PMID: 36161341. PMCID: PMC10509066. https://doi.org/10.1007/s00256-022-04191-6

  9. Ye J, Xie D, Li X, Lu N, Zeng C, Lei G, et al. Phenotypes of osteoarthritis-related knee pain and their transition over time: data from the osteoarthritis initiative. BMC Musculoskelet Disord. 2024;25(1):173.

    PMID: 38402384. PMCID: PMC10893610. https://doi.org/10.1186/s12891-024-07286-4

  10. Fugaru OF, Radulescu D, Șerbănescu MS, Traistaru MR. Phenotypic classification and functional assessment in knee osteoarthritis patients. Curr Health Sci J. 2024;50(2):299–309.

    PMID: 39371052. PMCID: PMC11447503. https://doi.org/10.12865/CHSJ.50.02.16

  11. Murray RO. The aetiology of primary osteoarthritis of the hip. Br J Radiol. 1965;38(455):810–24.

    PMID: 5842578. https://doi.org/10.1259/0007-1285-38-455-810

  12. Stulberg SD. Unrecognized childhood hip disease: A major cause of idiopathic osteoarthritis of the hip. In: Cordell LD, Harris WH, Ramsey PL, MacEwen GD, eds. Pressure distribution in the hip and selection of hemiarthroplasty. The hip: Proceedings of the Third Open Scientific Meeting of the Hip Society. St Louis, MO: CV Mosby. 1975:212–28.
  13. Ganz R, Leunig M, Leunig-Ganz K, Harris WH. The etiology of osteoarthritis of the hip: an integrated mechanical concept. Clin Orthop Relat Res. 200;466(2):264–72.

    PMID: 18196405. PMCID: PMC2505145. https://doi.org/10.1007/s11999-007-0060-z

  14. Lutter L, Serpell C J, Tuite M F, Serpell L C, Xue WF. Three-dimensional reconstruction of individual helical nano-filament structures from atomic force microscopy topographs. Biomolecular Concepts. 2020;11(1):102–15.

    PMID: 32374275. https://doi.org/10.1515/bmc-2020-0009

  15. Kalore NV. Editorial commentary: Myth buster – is femoral retroversion a contraindication to hip arthroscopy in femoroacetabular impingement? Arthroscopy. 2019;35(11):3047–48.

    PMID: 31699255. https://doi.org/10.1016/j.arthro.2019.08.017

  16. Faucett SC. Editorial commentary: Hip traumatic labrum tears: Does femoroacetabular impingement syndrome make a difference in outcome? Arthroscopy. 2020;36(1):176–77.

    PMID: 31864573. https://doi.org/10.1016/j.arthro.2019.11.002

  17. Luo X, Zhang J, Cai G, Wu Y, Ma K. Finite element analysis of femoral-acetabular impingement (FAI) based on three-dimensional reconstruction. J Healthc Eng. 2022;2022:2937056.

    PMID: 35265295. PMCID: PMC8898867. https://doi.org/10.1155/2022/2937056

  18. Beaule PE, O’Neill M, Rakhra K. Acetabular labral tears. J Bone Joint Surg Am. 2009;91(3):701–10.

    PMID: 19255234. https://doi.org/10.2106/JBJS.H.00802

  19. Beck M, Kalhor M, Leunig M, Ganz R. Hip morphology influences the pattern of damage to the acetabular cartilage: Femoroacetabular impingement as a cause of early osteoarthritis of the hip. J Bone Joint Surg Br. 2005;87(7):1012–18.

    PMID: 15972923. https://doi.org/10.1302/0301-620X.87B7.15203

  20. Tannast M, Siebenrock KA, Anderson SE. Femoroacetabular impingement: radiographic diagnosis – what the radiologist should know. AJR Am J Roentgenol. 2007;188(6):1540–52.

    PMID: 17515374. https://doi.org/10.2214/AJR.06.0921

  21. Murphy NJ, Eyles J, Spiers L, Davidson EJ, Linklater JM, Kim YJ, Hunter DJ. Combined femoral and acetabular version and synovitis are associated with dGEMRIC scores in people with femoroacetabular impingement (FAI) syndrome. J Orthop Res. 2023;41(11):2484–94.

    PMID: 37032588. PMCID: PMC10946968. https://doi.org/10.1002/jor.25568

  22. Li L, Sun K, Zhang L, Zhao Q, Cheng X, Dang Y. Heritability and sibling recurrent risk of developmental dysplasia of the hip in Chinese population. Eur J Clin Invest. 2013;43(6):589–94.

    PMID: 23550629. https://doi.org/10.1111/eci.12084

  23. Feldman GJ, Peters CL, Erickson JA, Hozack BA, Jaraha R, Parvizi J. Variable expression and incomplete penetrance of developmental dysplasia of the hip: Clinical challenge in a 71-member multigeneration family. J Arthroplasty. 2012;27(4):527–32.

    PMID: 22177793. https://doi.org/10.1016/j.arth.2011.10.016

  24. Пахомова Н.Ю., Строкова Е.Л., Кожевников В.В., Гусев А.Ф., Зайдман А.М. Врожденный вывих бедра – теории, этиологические и предрасполагающие факторы (факторы риска). Сибирский научный медицинский журнал. 2022;42(4):62–73. [Pakhomova NYu, Strokova EL, Kozhevnikov VV, Gusev AF, Zaydman AM. Congenital dislocation of the hip – theories, etiological and predisposing factors (risk factors). Sibirskiy nauchnyy meditsinskiy zhurnal = Siberian Scientific Medical Journal. 2022;42(4):62–73 (In Russ.)].

    EDN: HAMLVU. https://doi.org/10.18699/SSMJ20220405

  25. Pollard TC, Villar RN, Norton MR, Fern ED, Williams MR, Murray DW, Carr AJ. Genetic influences in the aetiology of femoroacetabular impingement: A sibling study. J Bone Joint Surg Br. 2010;92(2):209–16.

    PMID: 20130310. https://doi.org/10.1302/0301-620X.92B2.22850

  26. Shorter D, Hong T, Osborn DA. Cochrane review: Screening programmes for developmental dysplasia of the hip in newborn infants. Evid Based Child Health. 2013;8(1):11–54.

    PMID: 23878122. https://doi.org/10.1002/ebch.1891

  27. Oprișan A, Feier AM, Zuh SG, Russu OM, Pop TS. The presentation, clinical diagnosis, risk factors, and management of rapidly progressive hip osteoarthritis: A narrative literature review. J Clin Med. 2024;13(20):6194.

    PMID: 39458144. PMCID: PMC11509174.https://doi.org/10.3390/jcm13206194

  28. Zazgyva A, Gurzu S, Gergely I, Jung I, Roman CO, Pop TS. Clinico-radiological diagnosis and grading of rapidly progressive osteoarthritis of the hip. Medicine (Baltimore). 2017;96(12):e6395.

    PMID: 28328832. PMCID: PMC5371469. https://doi.org/10.1097/MD.0000000000006395

  29. Watanabe N, Ogawa T, Miyatake K, Takada R, Jinno T, Koga H, Yoshii T. Increased bone resorption that outpaces increased bone formation: An important pathology of rapidly destructive coxarthrosis. J Orthop Res. 2024;42(5):1066–73.

    PMID: 38044471. https://doi.org/10.1002/jor.25760

  30. Мироманов А.М., Забелло Т.В., Мироманова Н.А. Влияние полиморфизма генов IL4-589С>Т, FCGR2A166His>Arg, DEFB1-20G>A, DEFB1-52G>A на содержание TNFα, IL-1β, IL-4 и IL-10 у пациентов с первичным остеоартрозом тазобедренных суставов. Медицинская иммунология. 2020;22(5):1009–1016. [Miromanov AM, Zabello TV, Miromanova NA. Effect of IL4-589C>T, FCGR2A-166HIS>ARG, DEFB1-20G>A, DEFB1-52G>A gene polymorphisms on TNFα, IL-1β, IL-4, and IL-10 contents in the patients with primary hip osteoarthrosis. Meditsinskaya immunologiya = Medical Immunology (Russia). 2020;22(5):1009–1016 (In Russ.)].

    EDN: PRRAJQ. https://doi.org/10.15789/1563-0625-EOI-2034

  31. Yokota S, Shimizu T, Matsumae G, Ebata T, Alhasan H, Takahashi D, et al. Inflammasome activation in the hip synovium of rapidly destructive coxopathy patients and its relationship with the development of synovitis and bone loss. Am J Pathol. 2022;192(5):794–804.

    PMID: 35292262. https://doi.org/10.1016/j.ajpath.2022.02.003

  32. Yu YW, Li SY, Zhang LJ, Wang QL, Liu ZG, Chen QZ, et al. Retinoic acid receptor gamma (RARγ) promotes cartilage destruction through positive feedback activation of NF-κB pathway in human osteoarthritis. Mediat Inflamm. 2022;2022:1875736.

    PMID: 36387933. PMCID: PMC9663240. https://doi.org/10.1155/2022/1875736

  33. Molnar V, Matisic V, Kodvanj I, Bjelica R, Jelec Z, Hudetz D, et al. Cytokines and chemokines involved in osteoarthritis pathogenesis. Int J Mol Sci. 2021;22(17):9208.

    PMID: 34502117. PMCID: PMC8431625. https://doi.org/10.3390/ijms22179208

  34. Fowkes MM, Troeberg L, Brennan PE, Vincent TL, Meldal M, Lim NH. Development of selective ADAMTS-5 peptide substrates to monitor proteinase activity. J Med Chem. 2023;66(5):3522–39.

    PMID: 36891740. PMCID: PMC10009750. https://doi.org/10.1021/acs.jmedchem.2c02090

  35. Muratovic D, Atkins GJ, Findlay DM. Is RANKL a potential molecular target in osteoarthritis? Osteoarthritis Cartilage. 2024;32(5):493–500.

    PMID: 38160744. https://doi.org/10.1016/j.joca.2023.10.010

  36. Ando W, Hashimoto Y, Yasui H, Ogawa T, Koyama T, Tsuda T, Ohzono K. Progressive bone destruction in rapidly destructive coxopathy is characterized by elevated serum levels of matrix metalloprotease-3 and C-reactive protein. J Clin Rheumatol. 2022;28(1):e44–e48.

    PMID: 32956155. https://doi.org/10.1097/RHU.0000000000001578

  37. Altman RD, Bloch DA, Dougados M, Hochberg M, Lohmander S, Pavelka K, et al. Measurement of structural progression in osteoarthritis of the hip: The Barcelona consensus group. Osteoarthritis Cartilage. 2004;12(7):515–24.

    PMID: 15219566. https://doi.org/10.1016/j.joca.2004.04.004

  38. Boutin RD, Pai J, Meehan JP, Newman JS, Yao L. Rapidly progressive idiopathic arthritis of the hip: Incidence and risk factors in a controlled cohort study of 1471 patients after intra-articular corticosteroid injection. Skelet Radiol. 2021;50(12):2449–57.

    PMID: 34018006. https://doi.org/10.1007/s00256-021-03815-7

  39. Montero Furelos LA, De Castro Carrasco A, Cons Lamas S, Sanchez Sierra FB, Caeiro-Rey JR. Rapidly progressive osteoarthritis of the hip: A prospective study. J Clin Med. 2024;13(9):2467.

    PMID: 38730996. PMCID: PMC11084505. https://doi.org/10.3390/jcm13092467

  40. Okike K, King RK, Merchant JC, Toney EA, Lee GY, Yoon HC. Rapidly destructive hip disease following intra-articular corticosteroid injection of the hip. J Bone Joint Surg Am. 2021;103(22):2070–79.

    PMID: 34550909. https://doi.org/10.2106/JBJS.20.02155

  41. Nakamura K, Okamoto Y, Wakama H, Matsuyama J, Ishitani T, Otsuki S, Neo M. T1 pelvic angle is associated with rapid progression of hip arthrosis. Eur. Spine J. 2023;32(4):1463–70.

    PMID: 36800021. https://doi.org/10.1007/s00586-023-07580-0

  42. Karlsson MK, Magnusson H, Coster MC, Vonschewelov T, Karlsson C, Rosengren BE. Patients with hip osteoarthritis have a phenotype with high bone mass and low lean body mass. Clin Orthop Relat Res. 2014;472(4):1224–29.

    PMID: 24276858. PMCID: PMC3940750. https://doi.org/10.1007/s11999-013-3395-7

  43. Lanyon P, Muir K, Doherty S, Doherty M. Influence of radiographic phenotype on risk of hip osteoarthritis within families. Ann Rheum Dis. 2004;63(3):259–63.

    PMID: 14962959. PMCID: PMC1754908. https://doi.org/10.1136/ard.2002.003780

  44. Jiao Q, Swain S, Sarmanova A, Muir K, Zhang W, Doherty M. A cross-sectional study of associations between constitutional morphological features and individual radiographic phenotypes of hip osteoarthritis. Osteoarthritis and Cartilage. 2026;34(9):1372–79.

    PMID: 42119802. https://doi.org/10.1016/j.joca.2026.05.003

  45. Adik K, Campbell S, Srivastava A, Atkinson P, Atkinson T. Medial pole osteoarthritis series indicates moderate disease. J Orthop Rep. 2024;3(4):100349.

    https://doi.org/10.1016/j.jorep.2024.100349

  46. Kijima H, Yamada S, Konishi N, Kubota H, Tazawa H, Tani T, et al. The differences in imaging findings between painless and painful osteoarthritis of the hip. Clin Med Insights Arthritis Musculoskelet Disord. 2020;13:1179544120946747.

    PMID: 32821189. PMCID: PMC7412622. https://doi.org/10.1177/1179544120946747

  47. Gustafsson K, Kvist J, Eriksson M, Rolfson O. What factors identified in initial osteoarthritis management are associated with poor patient-reported outcomes after THA? A register-based study. Clin Orthop Relat Res. 2023;481(9):1732–42.

    PMID: 37159269. PMCID: PMC10427049. https://doi.org/10.1097/CORR.0000000000002681

  48. Tchetina E, Glemba K, Yunitskaya A, Markova G, Makarov M, Lila A. Cathepsin S upregulation measured in the peripheral blood mononuclear cells prior to surgery points to postoperative pain development in patients with hip osteoarthritis. Diagnostics (Basel). 2023;13(10):1739.

    PMID: 37238223. PMCID: PMC10217262. https://doi.org/10.3390/diagnostics13101739

  49. Jordans S, Jenko-Kokalj S, Kuhl NM, Tedelind S, Sendt W, Bromme D, et al. Monitoring compartment-specific substrate cleavage by cathepsins B, K, L and S at physiological pH and redox conditions. BMC Biochem. 2009;10:23.

    PMID: 19772638. PMCID: PMC2759951. https://doi.org/10.1186/1471-2091-10-23

  50. Clark AK, Malcangio M. Microglial signalling mechanisms: Cathepsin S and fractalkine. Exp Neurol. 2012;234(2):283–92.

    PMID: 21946268. https://doi.org/10.1016/j.expneurol.2011.09.012

  51. Svensson CI, Marsala M, Westerlund A, Calcutt NA, Campana WM, Freshwater JD, et al. Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation induced spinal pain processing. J Neurochem. 2003;86(6):1534–44.

    PMID: 12950462. https://doi.org/10.1046/j.1471-4159.2003.01969.x

  52. Pan F, Jones G. Clinical perspective on pain and pain phenotypes in osteoarthritis. Curr Rheumatol Rep. 2018;20(12):79.

    PMID: 30382417. https://doi.org/10.1007/s11926-018-0796-3

  53. Nijs J, George SZ, Clauw DJ, Fernández-De-Las-Penas C, Kosek E, Ickmans K, et al. Central sensitisation in chronic pain conditions: Latest discoveries and their potential for precision medicine. Lancet Rheumatol. 2021;3(5):e383–92.

    PMID: 38279393. https://doi.org/10.1016/S2665-9913(21)00032-1

  54. Sergooris A, Verbrugghe J, Bonnechere B, Klaps S, Matheve T, Vandeputte FJ, et al. Beyond the hip: Clinical phenotypes of hip osteoarthritis across the biopsychosocial spectrum. J Clin Med. 2024;13(22):6824.

    PMID: 39597968. PMCID: PMC11594843. https://doi.org/10.3390/jcm13226824

  55. Crombez G, Eccleston C, Van Damme S, Vlaeyen JW, Karoly P. Fear-avoidance model of chronic pain: The next generation. Clin J Pain. 2012;28(6):475–83.

    PMID: 22673479. https://doi.org/10.1097/AJP.0b013e3182385392

  56. Buirs LD, Beers LWAHV, Scholtes VAB, Pastoors T, Sprague S, Poolman RW. Predictors of physical functioning after total hip arthroplasty: A systematic review. BMJ Open. 2016;6(9):e010725.

    PMID: 27601486. PMCID: PMC5020746. https://doi.org/10.1136/bmjopen-2015-010725

  57. Sergooris A, Verbrugghe J, De Baets L, Meeus M, Roussel N, Smeets RJ, et al. Are contextual factors associated with activities and participation after total hip arthroplasty? A systematic review. Ann Phys Rehabil. Med. 2023;66(5):101712.

    PMID: 36680879. https://doi.org/10.1016/j.rehab.2022.101712

  58. de Rooij M, van der Leeden M, Heymans MW, Holla JF, Hakkinen A, Lems WF, et al. Course and predictors of pain and physical functioning in patients with hip osteoarthritis: Systematic review and meta-analysis. J Rehabil Med. 2016;48(3):245–52.

    PMID: 26871564. https://doi.org/10.2340/16501977-2057

  59. Teirlinck CH, Dorleijn DMJ, Bos PK, Rijkels-Otters JBM, Bierma-Zeinstra SMA, Luijsterburg PAJ. Prognostic factors for progression of osteoarthritis of the hip: A systematic review. Arthritis Res Ther. 2019;21(1):192.

    PMID: 31443685. PMCID: PMC6708123. https://doi.org/10.1186/s13075-019-1969-9

  60. Шилина В.Г., Выхристенко Л.Р. Внутрисуставные инъекции гиалуроновой кислоты в терапии остеоартрита коленного сустава: краткий обзор. Вестник Витебского государственного медицинского университета. 2025;24(3):9–17. [Shilina KG, Vykhrystenka LR. Intra-articular hyaluronic acid injections in the knee osteoarthritis therapy: A brief review. Vestnik Vitebskogo gosudarstvennogo meditsinskogo universiteta = Vitebsk Medical Journal. 2025;24(3):9–17 (In Russ.)].

    EDN: MUMYLS. https://doi.org/10.22263/2312-4156.2025.3.9

  61. Hashizume M, Mihara M. High molecular weight hyaluronic acid inhibits IL-6-induced MMP production from human chondrocytes by up-regulating the ERK inhibitor, MKP-1. Biochem Biophys Res Commun. 2010;403(2):184–89.

    PMID: 21059338. https://doi.org/10.1016/j.bbrc.2010.10.135

  62. Rayahin JE, Buhrman JS, Zhang Y, Koh TJ, Gemeinhart RA. High and low molecular weight hyaluronic acid differentially influence macrophage activation. ACS Biomater Sci Eng. 2015;1(7):481–93.

    PMID: 26280020. PMCID: PMC4533115. https://doi.org/10.1021/acsbiomaterials.5b00181

  63. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196(8):1025–37.

    PMID: 12391014. PMCID: PMC2194036. https://doi.org/10.1084/jem.20020760

  64. Сакс Л.А., Юдин В.А., Швецов В.В. Эффективность внутрисуставного введения гиалуроновой кислоты в комплексном лечении коксартроза. Вестник Национального медико-хирургического центра им. Н.И. Пирогова. 2013;8(1):43–45. [Saks LA, Yudin VA, Schwetsov VV. Intra-articular introduction of hyaluronic acid in treatment of osteoarthritis of the hip joints. Vestnik Natsional’nogo mediko-khirurgicheskogo tsentra imeni N.I. Pirogova = Bulletin of Pirogov National Medical and Surgical Center. 2013;8(1):43–45 (In Russ.)]. EDN: SIBYXF.
  65. Филатова Ю.С., Гауэрт В.Р. Гиалуроновая кислота при внутрисуставном введении: зависимость эффекта от молекулярной массы. РМЖ. Медицинское обозрение. 2021;5(3):156–161. [Filatova YuS, Gawert VR. Intra-articular hyaluronic acid: Dependence of the effect on molecular weight. Russkiy meditsinskiy zhurnal. Meditsinskoye obozreniye = Russian Medical Inquiry. 2021;5(3):156–161 (In Russ.)].

    EDN: FVUXXA. https://doi.org/10.32364/2587-6821-2021-5-3-156-161

  66. Wu YZ, Huang HT, Ho CJ, Shih CL, Chen CH, Cheng TL, et al Molecular weight of hyaluronic acid has major influence on its efficacy and safety for viscosupplementation in hip osteoarthritis: A systematic review and meta-analysis. Cartilage. 2021;13(1_suppl):169S–184S.

    PMID: 34109828. PMCID: PMC8808882. https://doi.org/10.1177/19476035211021903

  67. Altman R, Bedi A, Manjoo A, Niazi F, Shaw P, Mease P. Anti-inflammatory effects of intra-articular hyaluronic acid: A systematic review. Cartilage. 2019;10(1):43–52.

    PMID: 29429372. PMCID: PMC6376563. https://doi.org/10.1177/1947603517749919

  68. Bernetti A, Agostini F, Paoloni M, et al. Could hyaluronic acid be considered as a senomorphic agent in knee osteoarthritis? A systematic review. Biomedicines. 2023;11(10):2858.

    PMID: 37893231. PMCID: PMC10604344. https://doi.org/10.3390/biomedicines11102858

  69. De Lucia O, Luppino AF, Pregnolato F, Murgo A, Pontikaki I, Gattinara M, et al. Hyaluronic acid therapy in hip OA does not perform equally in osteoarthritis secondary to juvenile idiopathic arthritis when compared to primary osteoarthritis: A 2-year preliminary evaluation. Adv Ther. 2022;39(3):1267–78.

    PMID: 35038122. https://doi.org/10.1007/s12325-021-02020-1

  70. Santamaría Torroba A, Acin Lazaro MP, Gomez-Rubio E, Coronel Granado P. Efficacy and safety of one shot of hyaluronic acid in hip osteoarthritis: Postmarketing clinical follow-up for real-world evidence. Open Access Rheumatol. 2024;16:157–63.

    PMID: 39677564. PMCID: PMC11645952. https://doi.org/10.2147/OARRR.S485295

  71. Acuna AJ, Samuel LT, Jeong SH, Emara AK, Kamath AF. Viscosupplementation for hip osteoarthritis: Does systematic review of patient-reported outcome measures support use? J Orthop. 2020;21:137–49.

    PMID: 32255995. PMCID: PMC7114596. https://doi.org/10.1016/j.jor.2020.03.016

  72. Long DM, Fitzpatrick J. Safety and efficacy of a single intra-articular injection of hyaluronic acid in osteoarthritis of the hip: A case series of 87 patients. BMC Musculoskelet Disord. 2021;22(1):797.

    PMID: 34530784. PMCID: PMC8447787. https://doi.org/10.1186/s12891-021-04672-0

  73. Koyano G, Jinno T, Koga D, Hoshino C, Okawa A. Intra-articular injections of cross-linked hyaluronic acid in Japanese patients with symptomatic osteoarthritis of the hip. Prog Rehabil Med. 2021;6:20210038.

    PMID: 34632157. PMCID: PMC8476323. https://doi.org/10.2490/prm.20210038

  74. Призов А.П., Загородний Н.В., Лазко Ф.Л., Никитин А.А., Беляк Е.А., Лазко М.Ф. с соавт. Сравнение реологических и вязкоупругих свойств медицинских изделий гиалуроновой кислоты для внутрисуставного введения. Современная ревматология. 2023;17(2):50–56. [Prizov AP, Zagorodniy NV, Lazko FL, Nikitin AA, Belyak EA, Lazko MF, et al. Comparison of rheological and viscoelastic properties of hyaluronic acid for intraarticular injection. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2023;17(2):50–56 (In Russ.)].

    EDN: KQMOFB. https://doi.org/10.14412/1996-7012-2023-2-50-56

  75. Reichenbach S, Blank S, Rutjes AW, Shang A, King EA, Dieppe PA, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: A systematic review and meta-analysis. Arthritis Rheum. 2007;57(8):1410–18.

    PMID: 18050181. https://doi.org/10.1002/art.23103

  76. Инструкция по применению медицинского изделия ФЛЕКСОТРОН® Ультра М. Доступ: https://flexotron.ru/instruction (дата обращения – 15.09.2026). Instructions for use for FLEXOTRON® Ultra М medical device. URL: https://flexotron.ru/instruction (date of access – 15.09.2026) (In Russ.)].

About the Authors

Olga V. Teplyakova, MD, Dr. Sci. (Medicine), professor of the Department of polyclinic therapy, Ural Medical University; head of the Clinical Rheumatology Center of the Medical Association “New Hospital”, Ekaterinburg, Russian Federation.
Е-mail: oteplyakova69@gmail.com
ORCID: https://orcid.org/0000-0003-2114-0419. eLibrary SPIN: 3208-8679

Similar Articles